Ryvu Therapeutics (LTS:0RKT) LT-Debt-to-Total-Asset: 0.37 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0RKT Ryvu Therapeutics SA LTS:0RKT
66 GF Score
Price zł30.25
GF Value zł86.63
! 3 Warning Signs
View Full Analysis

What is Ryvu Therapeutics LT-Debt-to-Total-Asset?

Ryvu Therapeutics LTS:0RKT 66 LT-Debt-to-Total-Asset is 0.37 as of Mar. 2026. GuruFocus rates LTS:0RKT with a GF Score™ of 66/100 and a GF Value™ of zł86.63. The stock has 3 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Ryvu Therapeutics's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.37.

Ryvu Therapeutics's long-term debt to total assets ratio increased from Mar. 2025 (0.23) to Mar. 2026 (0.37). It may suggest that Ryvu Therapeutics is progressively becoming more dependent on debt to grow their business.

Ryvu Therapeutics  (LTS:0RKT) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Ryvu Therapeutics LT-Debt-to-Total-Asset Related Terms

Ryvu Therapeutics LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Ryvu Therapeutics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ryvu Therapeutics LT-Debt-to-Total-Asset Chart

Ryvu Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 0.00 0.00 0.18 0.32

Ryvu Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.23 0.24 0.27 0.32 0.37
LTS:0RKT
66GF Score
Ryvu Therapeutics SA LTS:0RKT
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ryvu Therapeutics LT-Debt-to-Total-Asset Calculation

Ryvu Therapeutics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )/Total Assets (A: Dec. 2025 )
=71.233/224.436
=0.32

Ryvu Therapeutics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )=Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )/Total Assets (Q: Mar. 2026 )
=73.252/200.955
=0.36

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.37 mean?
Ryvu Therapeutics (LTS:0RKT) has a LT-Debt-to-Total-Asset of 0.37 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Ryvu Therapeutics and its competitors.
Is Ryvu Therapeutics' LT-Debt-to-Total-Asset too high?
Ryvu Therapeutics' current LT-Debt-to-Total-Asset is 0.37. Overall, Ryvu Therapeutics has a GF Score™ of 66/100, reflecting its overall financial health beyond just this single metric.
How does Ryvu Therapeutics' LT-Debt-to-Total-Asset compare to VRTX and REGN?
Ryvu Therapeutics' LT-Debt-to-Total-Asset of 0.37 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Ryvu Therapeutics and its competitors. Ryvu Therapeutics's current LT-Debt-to-Total-Asset is 0.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ryvu Therapeutics stock overvalued right now?
Ryvu Therapeutics (LTS:0RKT) has a current LT-Debt-to-Total-Asset of 0.37. The stock's GF Value™ is zł86.63, compared to a current price of zł30.25 — trading 65.1% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.37. Ryvu Therapeutics' overall GF Score™ is 66/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Ryvu Therapeutics (LTS:0RKT), the current LT-Debt-to-Total-Asset is 0.37 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ryvu Therapeutics (LTS:0RKT) Overvalued in 2026?

Based on GuruFocus' analysis, Ryvu Therapeutics stock appears to be undervalued. The current stock price of zł30.25 is trading 65.1% below its estimated GF Value™ of zł86.63.

Key valuation signals for LTS:0RKT:

  • LT-Debt-to-Total-Asset: 0.37
  • GF Value™: zł86.63 vs. price of zł30.25 (65.1% below fair value)
  • GF Score™: 66/100 with 3 warning signs

No single metric tells the full story. See the LTS:0RKT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ryvu Therapeutics Business Description

Other Exchanges RVU:Poland9Y4:Germany
Address Leona Henryka Sternbacha 2, Krakow, POL, 30-394
Ryvu Therapeutics SA is a company which is engaged in discovering and developing small molecule therapies that address oncology. Its product candidate SEL120, is a kinase inhibitor with potential for development in hematological malignancies and solid tumors. The pipeline products of the company are developed in the areas of kinases, cancer metabolism, synthetic lethality, and immuno-oncology pathways.
66GF Score

Get the complete analysis for LTS:0RKT

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł30.25
Price
zł86.63
GF Value